Inflammatory skin diseases, such as acne, rosacea, atopic dermatitis, psoriasis, chronic wounds, are characterized by chronic remitting course, which remarkably reduces the quality of life of affected patients. The pathophysiology of these conditions is complex and multifactorial, involving elements of barrier dysfunction, alterations in the cell-mediated immune response. Its management is usually challenging since available treatments are not always capable of achieving significant results. Nonetheless, the introduction of biological drugs has certainly changed the approach to these pathologies.
Although these diseases may be grouped under a single heading of inflammatory skin disorders, there are many different molecular pathways involved, including multiple soluble interleukins and cellular receptors. Recent understanding of the pathogenesis of these diseases led to the introduction of targeted and highly effective therapies with encouraging results.
Our aim is to identify the most suitable therapies for the most frequent inflammatory skin diseases, in particular by selecting the therapeutic option according to the comorbidities and the degree of severity. The further objective is to highlight the novelties regarding the pathogenetic mechanisms underlying the onset of the aforementioned pathologies, as well as highlight the characteristics of patients who face therapeutic failures in order to better identify those mechanisms that can interfere with the efficacy of drugs used.
The scope of our Research Topic is to collect articles concerning the efficacy and the evaluation of the possible adverse events that occurred with new biological therapies used in chronic inflammatory skin diseases. In particular, we want to focus on the duration of clinical remission obtained by the new molecules in the different diseases and possible new therapeutic approaches for the diseases.
Inflammatory skin diseases, such as acne, rosacea, atopic dermatitis, psoriasis, chronic wounds, are characterized by chronic remitting course, which remarkably reduces the quality of life of affected patients. The pathophysiology of these conditions is complex and multifactorial, involving elements of barrier dysfunction, alterations in the cell-mediated immune response. Its management is usually challenging since available treatments are not always capable of achieving significant results. Nonetheless, the introduction of biological drugs has certainly changed the approach to these pathologies.
Although these diseases may be grouped under a single heading of inflammatory skin disorders, there are many different molecular pathways involved, including multiple soluble interleukins and cellular receptors. Recent understanding of the pathogenesis of these diseases led to the introduction of targeted and highly effective therapies with encouraging results.
Our aim is to identify the most suitable therapies for the most frequent inflammatory skin diseases, in particular by selecting the therapeutic option according to the comorbidities and the degree of severity. The further objective is to highlight the novelties regarding the pathogenetic mechanisms underlying the onset of the aforementioned pathologies, as well as highlight the characteristics of patients who face therapeutic failures in order to better identify those mechanisms that can interfere with the efficacy of drugs used.
The scope of our Research Topic is to collect articles concerning the efficacy and the evaluation of the possible adverse events that occurred with new biological therapies used in chronic inflammatory skin diseases. In particular, we want to focus on the duration of clinical remission obtained by the new molecules in the different diseases and possible new therapeutic approaches for the diseases.
